DuoGenic StemCells corporation
TWO: 7607.TWO0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- Taipei Exchange
- Sector
- Healthcare
- Industry
- Medical - Specialties
- CEO
- Chih Yao Lin
- Headquarters
- Taichung City, Taiwan
- IPO year
- 2023
- Market cap
- NT$512.0M
- Website
- http://www.dgsc.com.tw
Loading 7607…
Loading profile data…Frequently asked questions about 7607
What does DuoGenic StemCells corporation (7607.TWO) do?
Duogenic Stemcells Corp. engages in the provision of biotechnology and medical care services. It offers closed culture cell system and cell therapy services. The company was founded on March 22, 2018 and is headquartered in Taichung, Taiwan.
Where does 7607.TWO trade?
DuoGenic StemCells corporation (7607.TWO) trades on the Taipei Exchange.
What sector is 7607.TWO in?
DuoGenic StemCells corporation (7607.TWO) operates in the Healthcare sector, specifically in the Medical - Specialties industry.
Who is the CEO of DuoGenic StemCells corporation?
Chih Yao Lin is the chief executive officer of DuoGenic StemCells corporation (7607.TWO).
Where is DuoGenic StemCells corporation headquartered?
DuoGenic StemCells corporation is headquartered in Taiwan.
Does 7607.TWO pay a dividend?
DuoGenic StemCells corporation (7607.TWO) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did 7607.TWO go public?
DuoGenic StemCells corporation (7607.TWO) completed its initial public offering in 2023.